102821-72-7

Usage

Uses

Used in Organic Synthesis:
5-(2-FLUORO-PHENYL)-CYCLOHEXANE-1,3-DIONE is used as a building block in organic synthesis for the creation of various compounds. Its unique structure allows it to be a versatile component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-(2-FLUORO-PHENYL)-CYCLOHEXANE-1,3-DIONE is utilized as a precursor for the synthesis of potential drug candidates. Its chemical properties make it a promising starting material for the development of new medications.
Used as a Potential Anti-Inflammatory and Analgesic Agent:
5-(2-FLUORO-PHENYL)-CYCLOHEXANE-1,3-DIONE has been studied for its potential biological activity, showing promise as an anti-inflammatory and analgesic agent. Its ability to modulate biological responses makes it a candidate for further research in the development of pain relief and anti-inflammatory treatments.
Used in Material Science:
5-(2-FLUORO-PHENYL)-CYCLOHEXANE-1,3-DIONE has also been investigated for its potential use in material science. Its unique structure and properties could contribute to the development of new materials with specific characteristics for various applications.
Used as a Precursor for Synthesis of Functionalized Cyclohexanone Derivatives:
5-(2-FLUORO-PHENYL)-CYCLOHEXANE-1,3-DIONE serves as a precursor in the synthesis of functionalized cyclohexanone derivatives. These derivatives can have a range of applications, from pharmaceuticals to specialty chemicals, due to their diverse functional groups and potential reactivity.

InChI:InChI=1/C12H11FO2/c13-12-4-2-1-3-11(12)8-5-9(14)7-10(15)6-8/h1-4,8H,5-7H2

Upstream product

• 446-52-6 2-Fluorobenzaldehyde 
• 148775-25-1 4-(2-fluorophenyl)but-3-en-2-one 
• 105-53-3 diethyl malonate 

Downstream Products

• 239130-85-9 7-(2-fluorophenyl)-4-methyl-5,6,7,8-tetrahydroquinolin-5-one 
• 1083067-18-8 2-acetyl-5-(2-fluorophenyl)cyclohexane-1,3-dione 
• 1609374-94-8 5-(2-fluorophenyl)-2-(1-((2-methoxyphenyl)amino)ethylidene)cyclohexane-1,3-dione 

Relevant academic research and scientific papers

Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. Currently, there is only one FDA-approved treatment for ALS (riluzole), and that drug only extends life, on average, by 2-3 months. Mutations in Cu/Zn superoxide dismutase (SOD1) are found in familial forms of the disease and have played an important role in the study of ALS pathophysiology. On the basis of their activity in a PC12-G93A-YFP high-throughput screening assay, several bioactive compounds have been identified and classified as cyclohexane-1,3-dione (CHD) derivatives. A concise and efficient synthetic route has been developed to provide diverse CHD analogs. The structural modification of the CHD scaffold led to the discovery of a more potent analog (26) with an EC50 of 700 nM having good pharmacokinetic properties, such as high solubility, low human and mouse metabolic potential, and relatively good plasma stability. It was also found to efficiently penetrate the blood-brain barrier. However, compound 26 did not exhibit any significant life span extension in the ALS mouse model. It was found that, although 26 was active in PC12 cells, it had poor activity in other cell types, including primary cortical neurons, indicating that it can penetrate into the brain, but is not active in neuronal cells, potentially due to poor selective cell penetration. Further structural modification of the CHD scaffold was aimed at improving global cell activity as well as maintaining potency. Two new analogs (71 and 73) were synthesized, which had significantly enhanced cortical neuronal cell permeability, as well as similar potency to that of 26 in the PC12-G93A assay. These CHD analogs are being investigated further as novel therapeutic candidates for ALS.

QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS

Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLIC ENAMINONE DERIVATIVES

A process for the production of optically active cyclic enaminone derivatives characterized by aminating one of the carbonyl groups of a cyclic 1,3-diketone derivative having a symmetry plane to obtain an optically isomeric mixture of chiral cyclic enamin